ArticleFrontiers in oncology2025
Enhancing the accuracy of molecular classification of pediatric CNS tumors: a dual-classifier approach using DNA methylation profiling.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
DNA methylation-based classification has improved central nervous system (CNS) tumor diagnostics, but pediatric data on real-world implementation remain limited. We evaluated two DNA methylation-based classifiers-the Heidelberg classifier and the NIH/Bethesda (Methylscape) classifier-in a single-center cohort of pediatric patients. A total of 96 samples from 96 patients (75 CNS tumors, 10 non-CNS tumors, and 11 non-neoplastic CNS lesions) were profiled using Illumina MethylationEPIC arrays (850K/930K). We compared calibrated scores, concordance with integrated histopathological diagnoses, and the impact of technical factors such as tissue preservation, analyzable CpG count, and array version. Methylation classification agreed with integrated histopathology in 88.0% (66/75) of CNS tumors and refined diagnoses in 54.7% (41/75). Both classifiers showed high concordance but occasionally assigned high-confidence labels to non-neoplastic lesions, underscoring the importance of joint pathological review. Fresh frozen versus FFPE tissue, analyzable CpG count, and EPIC v1 versus v2 did not significantly affect classifier performance in our setting. Our findings support the use of methylation classifiers as decision-support tools in pediatric CNS tumor diagnostics, provided that calibrated score thresholds are interpreted in the context of tumor purity, DNA quality, and integrated neuropathology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.